Related Experiment Video
Updated: Apr 19, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer
F Selle1, J Gligorov1, S Richard1
1Medical Oncology and Cellular Therapy Department, Hospital Tenon, Public Assistance Hospitals of Paris, Alliance for Cancer Research (APREC), Paris, France.
Abstract:
Germ cell tumors present contrasting biological and molecular features compared to many solid tumors, which may partially explain their unusual sensitivity to chemotherapy. Reduced DNA repair capacity and enhanced induction of apoptosis appear to be key factors in the sensitivity of germ cell tumors to cisplatin. Despite substantial cure rates, some patients relapse and subsequently die of their disease. Intensive doses of chemotherapy are used to counter mechanisms of drug resistance. So far, high-dose chemotherapy with hematopoietic stem cell support for solid tumors is used only in the setting of testicular germ cell tumors. In that indication, high-dose chemotherapy is given as the first or late salvage treatment for patients with either relapsed or progressive tumors after initial conventional salvage chemotherapy. High-dose chemotherapy is usually given as two or three sequential cycles using carboplatin and etoposide with or without ifosfamide. The administration of intensive therapy carries significant side effects and can only be efficiently and safely conducted in specialized referral centers to assure optimum patient care outcomes. In breast and ovarian cancer, most studies have demonstrated improvement in progression-free survival (PFS), but overall survival remained unchanged. Therefore, most of these approaches have been dropped. In germ cell tumors, clinical trials are currently investigating novel therapeutic combinations and active treatments. In particular, the integration of targeted therapies constitutes an important area of research for patients with a poor prognosis.
Insights
Germ cell tumors show unique sensitivity to chemotherapy due to DNA repair and apoptosis factors. High-dose chemotherapy offers a vital salvage option for relapsed or progressive disease, improving outcomes.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Germ cell tumors (GCTs) exhibit distinct biological and molecular characteristics differentiating them from solid tumors.
- These unique features, including reduced DNA repair capacity and enhanced apoptosis induction, contribute to their notable sensitivity to chemotherapy, particularly cisplatin.
- Despite high cure rates, a subset of patients experience relapse, necessitating advanced treatment strategies.
Purpose of the Study:
- To review the role and efficacy of high-dose chemotherapy (HDC) with hematopoietic stem cell support in managing testicular germ cell tumors.
- To discuss the current landscape of therapeutic strategies for GCTs, including salvage treatments and emerging research areas.
- To highlight the importance of specialized centers for administering intensive cancer therapies safely and effectively.
Main Methods:
- Review of clinical trial data and literature on high-dose chemotherapy regimens for germ cell tumors.
- Analysis of treatment outcomes, including progression-free survival (PFS) and overall survival, in GCT patients undergoing HDC.
- Exploration of ongoing research into novel therapeutic combinations and targeted therapies for GCTs, especially for poor-prognosis cases.
Main Results:
- High-dose chemotherapy, typically using carboplatin and etoposide with or without ifosfamide, is established as a first-line or salvage treatment for relapsed/progressive testicular GCTs.
- While HDC has shown efficacy in GCTs, its application in other solid tumors like breast and ovarian cancer has yielded less consistent survival benefits.
- Intensive chemotherapy regimens carry significant toxicities, underscoring the need for administration in specialized cancer centers.
Conclusions:
- High-dose chemotherapy with stem cell support remains a critical therapeutic option for refractory or relapsed germ cell tumors.
- Ongoing clinical trials are focused on developing novel treatment combinations and integrating targeted therapies to improve outcomes for GCT patients with poor prognoses.
- Further research is essential to optimize GCT treatment paradigms and address mechanisms of drug resistance and therapeutic challenges.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy